Drugs / SR-8541A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06063681 | Oct 2023 → Dec 2025 overdue | metastatic neoplasm | Stingray Therapeutics | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06589440 | Nov 2024 → Sep 2027 expected | colorectal cancer | Stingray Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR-8541A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589440 ↗ |
| Action | Inhibit | “ENPP1 inhibitor” NCT06063681 ↗ |
| Route | Oral | “administered orally” NCT06063681 ↗ |